Anastrozole: Pharmacological and clinical profile in postmenopausal women with breast cancer

Expert Review of Anticancer Therapy

Volumn 1, Issue 2, 2001, Pages 169-176

  Köberle, Dieter ^a   Thürlimann, Beat ^a  

^a CANTONAL HOSPITAL ST GALLEN   (Switzerland)

Author keywords

Anastrozole Arimidex; Aromatase inhibitor; Breast cancer; Clinical trials; Pharmacology; Postmenopausal; Therapy

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; AROMATASE INHIBITOR; CYTOTOXIC AGENT; EXEMESTANE; FORMESTANE; LETROZOLE; MEGESTROL ACETATE; TAMOXIFEN;

ARTICLE; BREAST CANCER; CONTROLLED STUDY; DEPRESSION; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; FEMALE; HORMONAL THERAPY; HOT FLUSH; HUMAN; LETHARGY; NAUSEA AND VOMITING; POSTMENOPAUSE; SIDE EFFECT; VAGINA BLEEDING; WEIGHT GAIN;

EID: 0035559716     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737140.1.2.169     Document Type: Article

References (37)

1. Aromatase expression in health and disease
2. Aromatase, its inhibitors and their use in breast cancer treatment
3. Aromatase inhibitors in clinical practice current status and a look to the future
4. Aromatase inhibitors in relation to other forms of endocrine therapy for breast cancer
5. Use of aromatase inhibitors in breast carcinoma
6. The third-generation non-steroidal inhibitors: A review of their clinical benefits in the second-line hormonal treatment of advanced breast cancer
7. Aromatase inhibition with 4- hydroxyandrostenedione in the treatment of postmenopausal patients with advanced breast cancer. A Phase II study
8. Exemestane. A review of its use in postmenpausal women with advanced breast cancer
9. Aminoglutethimide in the treatment of advanced breast cancer
10. Anastrozole: A review of its use in the management of postmenopausal women with advanced breast cancer
11. Pharmacological and clinical profile of anastrozole
12. Letrozole. A review of its use in postmenopausal women with advanced breast cancer
13. Preclinical and clinical review of vorozole, a new third generation aromatase inhibitor
14. The preclinical pharmacology of 'Arimidex' (anastrozole; ZD1033) - A potent, selective aromatase inhibitor
15. Arimidex: A potent and selective fourth-generation aromatase inhibitor
16. Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer
17. A new nude mouse model for postmenopausal breast cancer using MCF-7 cells transfected with the human aromatase gene
18. The effects of aromatase inhibitors and anti-estrogens in the nude mouse model
19. Arimidex (ZD1033): A selective, potent inhibitor of aromatase in postmenopausal femal volunteers
20. A randomized comparison of estrogen suppression with anastrozole and formestane in postmenopausal patients with advanced breast cancer
21. A randomized trial comparing two doses of the new selective aromatase inhibitor (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer
22. A Phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma
23. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: Results of overview analysis of two Phase III trials
24. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: Results of a survival update based on a combined analysis of data from two mature Phase III trials
25. Anastrozole shows evidence of activity in postmenopausal patients who have responded or stabilised on formestane therapy
26. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: Results of a north american multicenter randomized trial
27. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: Results of the tamoxifen or arimidex randomized group efficacy and tolerability study
28. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: Findings highlight the importance of receptor status assessment prior to treatment indication
29. Anastrozole versus tamoxifen in hormono-dependent advanced breast cancer patients. A Phase II randomized trial
30. Efficacy of tamoxifen following Arimidex (anastrozole) as first-line treatment for advanced breast cancer in postmenopausal women
31. Arimidex as neoadjuvant therapy causes large reductions in tumor volume in postmenopausal women with large operable breast cancers
32. The effect of anastrozole (Arimidex™) on serum lipids - Data from randomized comparison of anastrozole vs. tamoxifen in postmenopausal women with advanced breast cancer
33. On the treatment of inoperale cases of carcinoma of the mamma: Suggestion for a new method of treatment, with illustrative cases
34. Tamoxifen in the treatment of breast cancer
35. Adjuvant therapy of primary breast cancer VI
36. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: Results of a Phase III study of the international letrozole breast cancer group
37. Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on amioglutethimide: A Phase II multicentre multinational study